Company · CIK 0001510580 · SIC 2836 — Biological Products, (No Diagnostic Substances)
Kite Pharma, Inc. · KITE
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 1, 2015 MForm 4 → | Jun 3, 7:38 pm EDT | Marc BetterVP, Product Sciences | 9,000 | $0.38 | $3,420 | 10,017 | — | plan? |
| May 27, 2015 SForm 4 → | May 29, 6:56 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | $50.59 | $505,934 | 74,566 | −11.8% | plan? |
| May 27, 2015 MForm 4 → | May 29, 6:56 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | $1.35 | $13,500 | 84,566 | — | plan? |
| May 15, 2015 SForm 4 → | May 19, 8:02 pm EDT | Margo R RobertsChief Scientific Officer | 8,625 | $50.17 | $432,709 | 999 | −89.6% | plan? |
| May 15, 2015 MForm 4 → | May 19, 8:02 pm EDT | Margo R RobertsChief Scientific Officer | 8,625 | $0.70 | $6,038 | 9,624 | — | plan? |
| May 15, 2015 SForm 4 → | May 19, 8:01 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | $50.15 | $451,339 | 1,218 | −88.1% | plan? |
| May 15, 2015 MForm 4 → | May 19, 8:01 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | $6.89 | $62,010 | 10,218 | — | plan? |
| May 15, 2015 SForm 4 → | May 19, 8:00 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | $50.16 | $479,867 | 1,695 | −84.9% | plan? |
| May 15, 2015 MForm 4 → | May 19, 8:00 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | $1.35 | $12,915 | 11,262 | — | plan? |
| May 1, 2015 SForm 4 → | May 5, 8:28 pm EDT | Marc BetterVP, Product Sciences | 9,000 | $50.72 | $456,451 | 1,017 | −89.8% | plan? |
| May 1, 2015 MForm 4 → | May 5, 8:28 pm EDT | Marc BetterVP, Product Sciences | 9,000 | $0.38 | $3,420 | 10,017 | — | plan? |
| Apr 27, 2015 MForm 4/A → | Apr 29, 9:54 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | $1.35 | $13,500 | 74,566 | — | plan? |
| Apr 27, 2015 SForm 4 → | Apr 29, 5:48 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | $59.76 | $597,624 | 64,566 | −13.4% | plan? |
| Mar 31, 2015 GForm 5 → | Feb 12, 2016, 4:46 pm EST | Joshua A KazamDirector | 222,500 | — | — | 215,000 | — | plan? |
| Mar 27, 2015 SForm 4 → | Mar 31, 8:38 pm EDT | Ran NussbaumDirector | 193,730 | $60.45 | $11,710,488 | 43,604 | −81.6% | plan? |
| Jun 25, 2014 PForm 4 → | Jun 17, 2015, 7:19 pm EDT | Jeffrey WiezorekVP Clinical Development | 4,000 | $17.00 | $68,000 | 5,218 | +328% | plan? late |
| Jun 25, 2014 PForm 4 → | Jun 17, 2015, 7:17 pm EDT | David D ChangEVP, R&D, Chief Medical Off. | 4,000 | $17.00 | $68,000 | 6,000 | +200% | plan? late |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 1, 2016 MForm 4 → | Feb 3, 7:04 pm EST | Marc BetterVP, Product Sciences | 9,000 | — | — | 60,000 | — | |
| Jan 27, 2016 MForm 4 → | Jan 29, 6:15 pm EST | Cynthia M ButittaCOO and CFO | 8,100 | — | — | 327,294 | — | |
| Jan 15, 2016 MForm 4 → | Jan 19, 8:24 pm EST | Jeffrey WiezorekSVP Clinical Development | 9,000 | — | — | 94,000 | — | |
| Jan 15, 2016 MForm 4 → | Jan 19, 8:23 pm EST | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 113,897 | — | |
| Jan 15, 2016 MForm 4 → | Jan 19, 8:22 pm EST | Margo R RobertsChief Scientific Officer | 6,145 | — | — | 32,588 | — | |
| Jan 4, 2016 MForm 4 → | Jan 5, 7:45 pm EST | Marc BetterVP, Product Sciences | 9,000 | — | — | 69,000 | — | |
| Dec 28, 2015 MForm 4 → | Dec 29, 7:17 pm EST | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 335,394 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:42 pm EST | Shawn TomaselloChief Commercial Officer | 160,000 | — | — | 160,000 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:40 pm EST | Marc BetterVP, Product Sciences | 8,800 | — | — | 8,800 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:39 pm EST | Rizwana F SprouleVP Regulatory Affairs | 8,800 | — | — | 8,800 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:38 pm EST | Margo R RobertsChief Scientific Officer | 24,800 | — | — | 24,800 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:37 pm EST | Jeffrey WiezorekSVP Clinical Development | 26,400 | — | — | 26,400 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:36 pm EST | Helen Susan KimEVP, Business Development | 33,000 | — | — | 33,000 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:36 pm EST | David D ChangEVP, R&D, Chief Medical Off. | 66,100 | — | — | 66,100 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:35 pm EST | Cynthia M ButittaCOO and CFO | 66,100 | — | — | 66,100 | — | |
| Dec 17, 2015 AForm 4 → | Dec 21, 8:34 pm EST | Arie BelldegrunChairman, President and CEO, Director, 10% Owner | 100,700 | — | — | 100,700 | — | |
| Dec 15, 2015 MForm 4 → | Dec 17, 7:33 pm EST | Jeffrey WiezorekSVP Clinical Development | 9,000 | — | — | 103,000 | — | |
| Dec 15, 2015 MForm 4 → | Dec 17, 7:33 pm EST | Margo R RobertsChief Scientific Officer | 6,145 | — | — | 33,233 | — | |
| Dec 15, 2015 MForm 4 → | Dec 17, 7:32 pm EST | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 123,464 | — | |
| Dec 1, 2015 MForm 4 → | Dec 3, 6:53 pm EST | Marc BetterVP, Product Sciences | 9,000 | — | — | 78,000 | — | |
| Nov 30, 2015 AMForm 4 → | Feb 18, 2016, 8:34 pm EST | Jeffrey WiezorekSVP Clinical Development | 34,000 | — | — | 16,000 | — | late |
| Nov 27, 2015 MForm 4 → | Nov 30, 8:23 pm EST | Cynthia M ButittaCOO and CFO | 15,000 | — | — | 345,394 | — | |
| Nov 16, 2015 MForm 4 → | Nov 18, 7:32 pm EST | Margo R RobertsChief Scientific Officer | 6,145 | — | — | 33,878 | — | |
| Nov 16, 2015 MForm 4 → | Nov 18, 7:31 pm EST | Jeffrey WiezorekSVP Clinical Development | 9,000 | — | — | 112,000 | — | |
| Nov 16, 2015 MForm 4 → | Nov 18, 7:29 pm EST | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 133,031 | — | |
| Nov 10, 2015 MForm 4 → | Nov 12, 6:33 pm EST | Cynthia M ButittaCOO and CFO | 5,000 | — | — | 360,394 | — | |
| Nov 10, 2015 MForm 4 → | Nov 12, 6:32 pm EST | David D ChangEVP, R&D, Chief Medical Off. | 30,800 | — | — | 223,000 | — | |
| Nov 2, 2015 MForm 4 → | Nov 4, 7:06 pm EST | Marc BetterVP, Product Sciences | 9,000 | — | — | 87,000 | — | |
| Nov 2, 2015 MForm 4 → | Nov 4, 7:05 pm EST | David D ChangEVP, R&D, Chief Medical Off. | 7,700 | — | — | 253,800 | — | |
| Oct 27, 2015 MForm 4 → | Oct 28, 7:17 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 365,394 | — | |
| Oct 15, 2015 MForm 4 → | Oct 19, 7:30 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 142,598 | — | |
| Oct 15, 2015 MForm 4 → | Oct 19, 7:29 pm EDT | Jeffrey WiezorekSVP Clinical Development | 9,000 | — | — | 121,000 | — | |
| Oct 15, 2015 MForm 4 → | Oct 19, 7:28 pm EDT | Margo R RobertsChief Scientific Officer | 6,145 | — | — | 34,523 | — | |
| Oct 1, 2015 MForm 4 → | Oct 2, 7:19 pm EDT | David D ChangEVP, R&D, Chief Medical Off. | 7,700 | — | — | 261,500 | — | |
| Oct 1, 2015 MForm 4 → | Oct 2, 7:18 pm EDT | Marc BetterVP, Product Sciences | 9,000 | — | — | 96,000 | — | |
| Sep 28, 2015 MForm 4 → | Sep 30, 7:01 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 375,394 | — | |
| Sep 15, 2015 MForm 4 → | Sep 17, 8:01 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | — | — | 130,000 | — | |
| Sep 15, 2015 MForm 4 → | Sep 17, 8:00 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 152,165 | — | |
| Sep 15, 2015 MForm 4 → | Sep 17, 7:59 pm EDT | Margo R RobertsChief Scientific Officer | 6,145 | — | — | 35,168 | — | |
| Sep 9, 2015 AForm 4 → | Sep 17, 1:48 pm EDT | Franz B HumerDirector | 20,000 | — | — | 20,000 | — | late |
| Sep 3, 2015 MForm 4 → | Sep 8, 7:14 pm EDT | David D ChangEVP, R&D, Chief Medical Off. | 7,700 | — | — | 269,200 | — | |
| Sep 1, 2015 MForm 4 → | Sep 3, 7:07 pm EDT | Marc BetterVP, Product Sciences | 9,000 | — | — | 105,000 | — | |
| Aug 27, 2015 MForm 4 → | Aug 28, 7:07 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 385,394 | — | |
| Aug 17, 2015 MForm 4 → | Aug 19, 8:04 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | — | — | 139,000 | — | |
| Aug 17, 2015 MForm 4 → | Aug 19, 8:03 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 161,732 | — | |
| Aug 17, 2015 MForm 4 → | Aug 19, 8:01 pm EDT | Margo R RobertsChief Scientific Officer | 6,145 | — | — | 35,813 | — | |
| Aug 3, 2015 MForm 4 → | Aug 4, 7:30 pm EDT | Marc BetterVP, Product Sciences | 9,000 | — | — | 114,000 | — | |
| Aug 3, 2015 MForm 4 → | Aug 4, 7:29 pm EDT | David D ChangEVP, R&D, Chief Medical Off. | 7,700 | — | — | 276,900 | — | |
| Jul 27, 2015 MForm 4 → | Jul 28, 7:03 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 395,394 | — | |
| Jul 15, 2015 MForm 4 → | Jul 23, 2:29 pm EDT | Margo R RobertsChief Scientific Officer | 22,167 | — | — | 36,458 | — | late |
| Jul 15, 2015 MForm 4 → | Jul 20, 9:03 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | — | — | 148,000 | — | late |
| Jul 15, 2015 MForm 4 → | Jul 20, 9:02 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 171,299 | — | late |
| Jul 1, 2015 MForm 4 → | Jul 2, 8:36 pm EDT | Marc BetterVP, Product Sciences | 9,000 | — | — | 123,000 | — | |
| Jul 1, 2015 MForm 4 → | Jul 2, 8:35 pm EDT | David D ChangEVP, R&D, Chief Medical Off. | 7,700 | — | — | 284,600 | — | |
| Jun 29, 2015 MForm 4 → | Jul 1, 7:15 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 405,394 | — | |
| Jun 15, 2015 MForm 4 → | Jun 17, 7:19 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | — | — | 157,000 | — | |
| Jun 15, 2015 MForm 4 → | Jun 17, 7:17 pm EDT | David D ChangEVP, R&D, Chief Medical Off. | 7,700 | — | — | 292,300 | — | |
| Jun 15, 2015 MForm 4 → | Jun 17, 7:16 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 180,866 | — | |
| Jun 15, 2015 MForm 4 → | Jun 17, 7:15 pm EDT | Margo R RobertsChief Scientific Officer | 8,625 | — | — | 132,750 | — | |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:13 pm EDT | Roy DoumaniDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:11 pm EDT | Steven B RuchefskyDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:09 pm EDT | Jonathan M PeacockDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:08 pm EDT | Ran NussbaumDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:07 pm EDT | Joshua A KazamDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:04 pm EDT | Farah ChampsiDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 9, 2015 AForm 4 → | Jun 17, 7:03 pm EDT | David BondermanDirector | 10,000 | — | — | 10,000 | — | late |
| Jun 1, 2015 MForm 4 → | Jun 3, 7:38 pm EDT | Marc BetterVP, Product Sciences | 9,000 | — | — | 132,000 | — | |
| May 27, 2015 MForm 4 → | May 29, 6:56 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 415,394 | — | |
| May 19, 2015 AMForm 4 → | Aug 16, 2016, 8:16 pm EDT | Helen Susan KimEVP, Business Development | 155,900 | — | — | 84,100 | — | late |
| May 15, 2015 MForm 4 → | May 19, 8:02 pm EDT | Margo R RobertsChief Scientific Officer | 8,625 | — | — | 141,375 | — | |
| May 15, 2015 MForm 4 → | May 19, 8:01 pm EDT | Jeffrey WiezorekVP Clinical Development | 9,000 | — | — | 166,000 | — | |
| May 15, 2015 MForm 4 → | May 19, 8:00 pm EDT | Rizwana F SprouleVP Regulatory Affairs | 9,567 | — | — | 190,433 | — | |
| May 1, 2015 MForm 4 → | May 5, 8:28 pm EDT | Marc BetterVP, Product Sciences | 9,000 | — | — | 141,000 | — | |
| Apr 27, 2015 MForm 4/A → | Apr 29, 9:54 pm EDT | Cynthia M ButittaCOO and CFO | 10,000 | — | — | 425,394 | — |